Cargando…

Coproporphyrin I as an Endogenous Biomarker to Detect Reduced OATP1B Activity and Shift in Elimination Route in Chronic Kidney Disease

Coproporphyrin I (CPI) is an endogenous biomarker of organic anion transporting polypeptide 1B transporter (OATP1B). CPI plasma baseline was reported to increase with severity of chronic kidney disease (CKD). Further, ratio of CPI area under the plasma concentration‐time curve (AUCR) in the presence...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takita, Hiroyuki, Scotcher, Daniel, Chu, Xiaoyan, Yee, Ka Lai, Ogungbenro, Kayode, Galetin, Aleksandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540787/ https://www.ncbi.nlm.nih.gov/pubmed/35652251 http://dx.doi.org/10.1002/cpt.2672

Ejemplares similares

Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B‐Mediated Drug–Drug Interactions Using Population Pharmacokinetic Modeling and Simulation
por: Barnett, Shelby, et al.
Publicado: (2018)

PBPK Model of Coproporphyrin I: Evaluation of the Impact of SLCO1B1 Genotype, Ethnicity, and Sex on its Inter‐Individual Variability
por: Takita, Hiroyuki, et al.
Publicado: (2021)

Quantification of OATP1B1 endogenous metabolites coproporphyrin I and III in human urine
por: Jang, Yeonseo, et al.
Publicado: (2023)

PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3
por: Yoshikado, Takashi, et al.
Publicado: (2018)

Relationship of hemoglobin level and plasma coproporphyrin‐I concentrations as an endogenous probe for phenotyping OATP1B
por: Suzuki, Yosuke, et al.
Publicado: (2021)

Performance of Plasma Coproporphyrin I and III as OATP1B1 Biomarkers in Humans
por: Neuvonen, Mikko, et al.
Publicado: (2021)

Physiologically‐based pharmacokinetic model‐based translation of OATP1B‐mediated drug–drug interactions from coproporphyrin I to probe drugs
por: Mochizuki, Tatsuki, et al.
Publicado: (2022)

Coproporphyrin I Can Serve as an Endogenous Biomarker for OATP1B1 Inhibition: Assessment Using a Glecaprevir/Pibrentasvir Clinical Study
por: Kalluri, Hari V., et al.
Publicado: (2020)

Physiologically‐Based Pharmacokinetic Modelling of Creatinine‐Drug Interactions in the Chronic Kidney Disease Population
por: Takita, Hiroyuki, et al.
Publicado: (2020)

Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats
por: Scotcher, Daniel, et al.
Publicado: (2021)

Population pharmacokinetic modeling and simulation to support qualification of pyridoxic acid as endogenous biomarker of OAT1/3 renal transporters
por: Ahmad, Amais, et al.
Publicado: (2021)

Substantially Increased Plasma Coproporphyrin‐I Concentrations Associated With OATP1B1*15 Allele in Japanese General Population
por: Suzuki, Yosuke, et al.
Publicado: (2020)

Cluster Gauss‐Newton method analyses of PBPK model parameter combinations of coproporphyrin‐I based on OATP1B‐mediated rifampicin interaction studies
por: Yoshikado, Takashi, et al.
Publicado: (2022)

Crystal structures and calorimetry reveal catalytically relevant binding mode of coproporphyrin and coproheme in coproporphyrin ferrochelatase
por: Hofbauer, Stefan, et al.
Publicado: (2019)

PBPK Simulation-Based Evaluation of Ganciclovir Crystalluria Risk Factors: Effect of Renal Impairment, Old Age, and Low Fluid Intake
por: Scotcher, Daniel, et al.
Publicado: (2021)

A population pharmacokinetic model for simvastatin and its metabolites in children and adolescents
por: Ogungbenro, Kayode, et al.
Publicado: (2019)

Active site architecture of coproporphyrin ferrochelatase with its physiological substrate coproporphyrin III: Propionate interactions and porphyrin core deformation
por: Dali, Andrea, et al.
Publicado: (2023)

Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP
por: Tan, Ming‐Liang, et al.
Publicado: (2017)

Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations
por: Scotcher, Daniel, et al.
Publicado: (2017)

Use of In Vivo Imaging and Physiologically-Based Kinetic Modelling to Predict Hepatic Transporter Mediated Drug–Drug Interactions in Rats
por: Melillo, Nicola, et al.
Publicado: (2023)

Urinary Elimination of Coproporphyrins Is Dependent on ABCC2 Polymorphisms and Represents a Potential Biomarker of MRP2 Activity in Humans
por: Benz-de Bretagne, Isabelle, et al.
Publicado: (2011)

Model‐Based Drug–Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy
por: Cleary, Yumi, et al.
Publicado: (2021)

Effect of Chronic Kidney Disease on the Renal Secretion via Organic Anion Transporters 1/3: Implications for Physiologically‐Based Pharmacokinetic Modeling and Dose Adjustment
por: Tan, Shawn Pei Feng, et al.
Publicado: (2022)

Novel minimal physiologically-based model for the prediction of passive tubular reabsorption and renal excretion clearance
por: Scotcher, Daniel, et al.
Publicado: (2016)

Various effects of repeated rifampin dosing on coproporphyrin levels in humans
por: Kinzi, Jonny, et al.
Publicado: (2023)

In Vitro to In Vivo Extrapolation Linked to Physiologically Based Pharmacokinetic Models for Assessing the Brain Drug Disposition
por: Murata, Yukiko, et al.
Publicado: (2022)

Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Effect of Chronic Kidney Disease on the Disposition of Hepatic CYP2C8 and OATP1B Drug Substrates
por: Tan, Ming‐Liang, et al.
Publicado: (2018)

Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug–Drug Interactions in Children
por: Cleary, Yumi, et al.
Publicado: (2023)

Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug Interactions
por: Mochizuki, Tatsuki, et al.
Publicado: (2022)

Propionibacterium-Produced Coproporphyrin III Induces Staphylococcus aureus Aggregation and Biofilm Formation
por: Wollenberg, Michael S., et al.
Publicado: (2014)

Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination
por: Eisenmann, Eric D., et al.
Publicado: (2022)

The coproporphyrin ferrochelatase of Staphylococcus aureus: mechanistic insights into a regulatory iron-binding site
por: Hobbs, Charlie, et al.
Publicado: (2017)

Iron insertion into coproporphyrin III‐ferrochelatase complex: Evidence for an intermediate distorted catalytic species
por: Gabler, Thomas, et al.
Publicado: (2023)

Microsomal and Cytosolic Scaling Factors in Dog and Human Kidney Cortex and Application for In Vitro-In Vivo Extrapolation of Renal Metabolic Clearance
por: Scotcher, Daniel, et al.
Publicado: (2017)

Structure of human drug transporters OATP1B1 and OATP1B3
por: Ciută, Anca-Denise, et al.
Publicado: (2023)

Quantitative Prediction of OATP‐Mediated Drug‐Drug Interactions With Model‐Based Analysis of Endogenous Biomarker Kinetics
por: Yoshida, Kenta, et al.
Publicado: (2018)

Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1
por: Nies, Anne T, et al.
Publicado: (2013)

Coproporphyrin III Produced by the Bacterium Glutamicibacter arilaitensis Binds Zinc and Is Upregulated by Fungi in Cheese Rinds
por: Cleary, Jessica L., et al.
Publicado: (2018)

Measuring acne using Coproporphyrin III, Protoporphyrin IX, and lesion-specific inflammation: an exploratory study
por: Patwardhan, Sachin V., et al.
Publicado: (2017)

Physiologically‐based pharmacokinetic modeling for investigating the effect of simeprevir on concomitant drugs and an endogenous biomarker of OATP1B
por: Nakayama, Shinji, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_22sk8i40khqajgmal0qkj0t6d7